European Investor
28 Mar 2026, 07:23
Eli Lilly and Company reported new long-term data showing that EBGLYSS delivered sustained disease control for patients with moderate-to-severe atopic dermatitis for up to four years.
Results from the ADlong Phase 3b study indicated that nearly all treated patients achieved meaningful skin improvement, with 75% reaching near-complete skin clearance and 78% experiencing significant itch relief. Around 80% of patients maintained results without the need for topical corticosteroids.
The treatment, an IL-13 inhibitor targeting underlying inflammation, demonstrated a safety profile consistent with previous studies, with most adverse events being mild or moderate.
The findings reinforce EBGLYSS’s potential as a long-term treatment option, supporting durable symptom control and reduced disease flares in patients with chronic eczema.
PRNewswire
Results from the ADlong Phase 3b study indicated that nearly all treated patients achieved meaningful skin improvement, with 75% reaching near-complete skin clearance and 78% experiencing significant itch relief. Around 80% of patients maintained results without the need for topical corticosteroids.
The treatment, an IL-13 inhibitor targeting underlying inflammation, demonstrated a safety profile consistent with previous studies, with most adverse events being mild or moderate.
The findings reinforce EBGLYSS’s potential as a long-term treatment option, supporting durable symptom control and reduced disease flares in patients with chronic eczema.
PRNewswire